CN1213314A - 通过对眼的光动力学治疗改善视力 - Google Patents
通过对眼的光动力学治疗改善视力 Download PDFInfo
- Publication number
- CN1213314A CN1213314A CN97192957A CN97192957A CN1213314A CN 1213314 A CN1213314 A CN 1213314A CN 97192957 A CN97192957 A CN 97192957A CN 97192957 A CN97192957 A CN 97192957A CN 1213314 A CN1213314 A CN 1213314A
- Authority
- CN
- China
- Prior art keywords
- photoactive compounds
- green porphyrin
- experimenter
- alkoxy carbonyl
- carbonyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
Description
治疗方案A | 治疗方案B | 治疗方案C | |
典型的CNV≥50%封闭 | +0.7(3/20) | +3(4/13) | -(0/12) |
典型的CNV<50%封闭 | +0.14(7/20) | 0(3/13) | +1.75(4/12) |
典型的CNV复发 | -0.1(10/20) | -0.3(6/13) | -1.4(8/12) |
Claims (13)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/613,420 | 1996-03-11 | ||
US08/613,420 US5756541A (en) | 1996-03-11 | 1996-03-11 | Vision through photodynamic therapy of the eye |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1213314A true CN1213314A (zh) | 1999-04-07 |
CN1104908C CN1104908C (zh) | 2003-04-09 |
Family
ID=24457246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN97192957A Expired - Lifetime CN1104908C (zh) | 1996-03-11 | 1997-02-25 | 通过对眼的光动力学治疗改善视力 |
Country Status (22)
Country | Link |
---|---|
US (6) | US5756541A (zh) |
EP (1) | EP0894009B1 (zh) |
JP (2) | JP2000506173A (zh) |
KR (1) | KR100433507B1 (zh) |
CN (1) | CN1104908C (zh) |
AR (2) | AR004422A1 (zh) |
AT (1) | ATE301473T1 (zh) |
CA (1) | CA2248087C (zh) |
CZ (1) | CZ299301B6 (zh) |
DE (1) | DE69733943T2 (zh) |
DK (1) | DK0894009T3 (zh) |
ES (1) | ES2246505T3 (zh) |
FI (1) | FI981954A (zh) |
HK (1) | HK1018203A1 (zh) |
HU (1) | HU227978B1 (zh) |
IL (4) | IL126099A (zh) |
NO (1) | NO984163L (zh) |
NZ (1) | NZ331736A (zh) |
PL (1) | PL188888B1 (zh) |
TW (1) | TW448045B (zh) |
WO (1) | WO1997033619A1 (zh) |
ZA (1) | ZA971820B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005018634A1 (fr) * | 2003-08-25 | 2005-03-03 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Ether de monomethyle d'hematoporphyrine utilise pour le traitement de troubles oculaires |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6270749B1 (en) | 1996-12-11 | 2001-08-07 | Pharmacyclics, Inc. | Use of Texaphyrin in ocular diagnosis and therapy |
CA2278937A1 (en) * | 1996-12-11 | 1998-06-18 | Pharmacyclics, Inc. | Use of a texaphyrin in the preparation of a medicament for use in ocular diagnosis and therapy |
US6274614B1 (en) | 1997-02-11 | 2001-08-14 | Qlt Inc. | Methods, compositions and articles for reducing or preventing the effects of inflammation |
CZ295734B6 (cs) * | 1997-02-11 | 2005-10-12 | Qlt Inc. | Léčivo pro omezení nebo prevenci účinků zánětů v tkáni |
US6117862A (en) * | 1998-10-09 | 2000-09-12 | Qlt, Inc. | Model and method for angiogenesis inhibition |
US7022843B1 (en) | 1999-04-14 | 2006-04-04 | The University Of British Columbia | β,β′-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins |
US20020022032A1 (en) * | 1999-04-23 | 2002-02-21 | Curry Patrick Mark | Immuno-adjuvant PDT treatment of metastatic tumors |
US6443976B1 (en) | 1999-11-30 | 2002-09-03 | Akorn, Inc. | Methods for treating conditions and illnesses associated with abnormal vasculature |
US7897140B2 (en) | 1999-12-23 | 2011-03-01 | Health Research, Inc. | Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents |
US6534040B2 (en) | 1999-12-23 | 2003-03-18 | Health Research, Inc. | Chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals |
US7078014B2 (en) * | 1999-12-23 | 2006-07-18 | Health Research, Inc. | Method for using chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals |
US7097826B2 (en) | 1999-12-23 | 2006-08-29 | Health Research, Inc. | Chlorin and bacteriochlorin-based difunctional aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals |
WO2001051087A2 (en) * | 2000-01-12 | 2001-07-19 | Light Sciences Corporation | Novel treatment for eye disease |
ATE552855T1 (de) | 2000-02-10 | 2012-04-15 | Massachusetts Eye & Ear Infirm | Kombinationen und zubereitung zur anwendung in pdt zur behandlung von augenleiden mit unerwünschter choriodaler neovascularisation |
AU2006203034B2 (en) * | 2000-02-10 | 2006-09-07 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
WO2001074389A2 (en) * | 2000-03-24 | 2001-10-11 | Novartis Ag | Improved treatment of neovascularization |
AU2002248284A1 (en) * | 2000-11-01 | 2002-08-06 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
US20030082183A1 (en) * | 2000-11-01 | 2003-05-01 | Wheeler Larry A. | Methods and compositions for treatment of ocular neovascularization and neural injury |
US7753943B2 (en) * | 2001-02-06 | 2010-07-13 | Qlt Inc. | Reduced fluence rate PDT |
DE60225783T2 (de) * | 2001-02-06 | 2009-04-09 | Qlt Inc., Vancouver | Photodynamische therapie mit verminderter bestrahlungsstärke |
US8106038B2 (en) | 2001-02-15 | 2012-01-31 | Qlt Inc. | Method for reducing or preventing PDT related inflammation |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
US6599891B2 (en) * | 2001-07-20 | 2003-07-29 | Qlt Inc. | Treatment of macular edema |
WO2003039404A2 (en) * | 2001-11-09 | 2003-05-15 | Eyetech Pharmaceuticals | Methods for treating ocular neovascular diseases |
WO2003061696A2 (en) * | 2002-01-23 | 2003-07-31 | Light Sciences Corporation | Systems and methods for photodynamic therapy |
BR0308675A (pt) * | 2002-03-20 | 2005-02-15 | Novadaq Technologies Inc | Método e aparelho para visualizar o fluxo de fluido através de vasos, memória que pode ser lida por computador, produto de programa de computador e método para o tratamento de uma lesão de um animal |
US7381404B2 (en) * | 2002-07-02 | 2008-06-03 | The Regents Of The University Of California | Treatment for dry macular degeneration |
CA2499469C (en) * | 2002-07-17 | 2013-06-04 | Novadaq Technologies Inc. | Combined photocoagulation and photodynamic therapy |
CA2500877A1 (en) * | 2002-10-03 | 2004-04-15 | Light Sciences Corporation | Excitation of photoreactive compounds in eye tissue |
US20060258629A1 (en) * | 2002-10-18 | 2006-11-16 | Freeman William R | Photodynamic therapy for ocular neovascularization |
US20060141470A1 (en) * | 2003-02-14 | 2006-06-29 | Kalayoglu Murat V | Chlamydia pneumoniae associated chronic intraocular disorders and treatment thereof |
ATE442861T1 (de) * | 2003-03-07 | 2009-10-15 | Univ Texas | Gegen antikörper gerichtete photodynamische therapie |
US20040220167A1 (en) * | 2003-05-02 | 2004-11-04 | Nasrollah Samiy | Methods of treating neuralgic pain |
JP4855937B2 (ja) * | 2003-05-14 | 2012-01-18 | ソシエテ デ コマーシャリセーション デス プロデューツ デ ラ リーサーシェ アプリケ エスオーシーピーアールエー−サイエンセス サンテ エ ヒューマネス エス.イー.シー. | 医療における光線力学適用のための両親媒性トリスルホン化ポルフィラジン |
US20050048109A1 (en) * | 2003-08-26 | 2005-03-03 | Ceramoptec Industries, Inc. | Non-polar photosensitizer formulations for photodynamic therapy |
WO2005066348A2 (en) | 2004-01-05 | 2005-07-21 | Emd Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
US20050244466A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Photodynamic therapy in conjunction with intraocular implants |
EP1755584A4 (en) * | 2004-05-07 | 2007-10-31 | Univ California | TREATMENT OF MYOPIA |
WO2006020979A2 (en) * | 2004-08-13 | 2006-02-23 | Yale University | Factor vii conjugates for selectively treating neovascularization disorders |
US20070213693A1 (en) * | 2004-08-27 | 2007-09-13 | Ellex Medical Pty Ltd | Selective ophthalmic laser treatment |
TW200610555A (en) * | 2004-09-24 | 2006-04-01 | Light Sciences Corp | Extended treatment of tumors through vessel occlusion with light activated drugs |
CN103301094A (zh) * | 2004-11-17 | 2013-09-18 | 乔安妮·麦克劳林 | 用于治疗蛋白聚集疾病的含鲨肌醇衍生物的组合物和方法 |
JP2008524224A (ja) * | 2004-12-15 | 2008-07-10 | ライト サイエンシズ オンコロジー、インコーポレイテッド | 閉塞作用を強化した光線力学的療法 |
US7803375B2 (en) * | 2005-02-23 | 2010-09-28 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
US20070122344A1 (en) | 2005-09-02 | 2007-05-31 | University Of Rochester Medical Center Office Of Technology Transfer | Intraoperative determination of nerve location |
WO2007119108A2 (en) * | 2005-10-13 | 2007-10-25 | Waratah Pharmaceuticals Inc. | Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence |
WO2007097961A1 (en) * | 2006-02-16 | 2007-08-30 | Massachusetts Eye & Ear Infirmary | Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage |
WO2007097839A2 (en) * | 2006-02-16 | 2007-08-30 | Massachusetts Eye And Ear Infirmary | Ansamycin analogs or heat shock 90 inhibitors in combination with pdt treatin conditions of the eye |
US20070197452A1 (en) * | 2006-02-17 | 2007-08-23 | Mclaurin Joanne | Treatment of amyloid-related diseases |
JP2009526834A (ja) * | 2006-02-17 | 2009-07-23 | ジョアン マクローリン, | タンパク質凝集の疾患の治療のための組成物および方法 |
BRPI0708725A2 (pt) * | 2006-03-09 | 2011-06-07 | Waratah Pharmaceuticals Inc | formulação de poliálcool de ciclohexano para o tratamento de doenças de agregação de proteìna |
CA2652449A1 (en) * | 2006-05-19 | 2007-11-29 | Waratah Pharmaceuticals Inc. | Screening methods for amyloid beta modulators |
US20080161744A1 (en) | 2006-09-07 | 2008-07-03 | University Of Rochester Medical Center | Pre-And Intra-Operative Localization of Penile Sentinel Nodes |
US20100173960A1 (en) * | 2006-09-21 | 2010-07-08 | Antonio Cruz | The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases |
EP2083777A4 (en) | 2006-10-25 | 2011-01-05 | Ellex R & D Pty Ltd | RETINAL REGENERATION |
JP2010510254A (ja) * | 2006-11-24 | 2010-04-02 | ワラタ ファーマシューティカルズ, インコーポレイテッド | アルツハイマー病および関連の神経変性疾患のための併用処置 |
WO2008103299A2 (en) * | 2007-02-16 | 2008-08-28 | Massachusetts Eye & Ear Infirmary | Methods and compositions for prognosing, detecting, and treating age-related macular degeneration |
WO2008124931A1 (en) * | 2007-04-12 | 2008-10-23 | Joanne Mclaurin | Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis |
CA2683548A1 (en) * | 2007-04-12 | 2008-10-23 | Joanne Mclaurin | Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases |
US20100331267A1 (en) * | 2007-04-12 | 2010-12-30 | Mclaurin Joanne | Use of cyclohexanehexol derivatives in the treatment of alpha-synucleinopathies |
EP2148667B1 (en) * | 2007-04-12 | 2013-05-22 | Waratah Pharmaceuticals, Inc. | Use of cyclohexanehexol derivatives in the treatment of ocular diseases |
AU2008255642B2 (en) * | 2007-05-30 | 2013-03-07 | Alpharet Pty Ltd | Retinal rejuvenation laser |
US20090170770A1 (en) * | 2007-11-06 | 2009-07-02 | Ali Hafezi-Moghadam | Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor |
US8406860B2 (en) | 2008-01-25 | 2013-03-26 | Novadaq Technologies Inc. | Method for evaluating blush in myocardial tissue |
WO2009126894A2 (en) * | 2008-04-11 | 2009-10-15 | Massachusetts Eye And Ear Infirmary | Methods and compositions for the diagnosis and treatment of angiogenic disorders |
US10219742B2 (en) | 2008-04-14 | 2019-03-05 | Novadaq Technologies ULC | Locating and analyzing perforator flaps for plastic and reconstructive surgery |
ES2671710T3 (es) | 2008-05-02 | 2018-06-08 | Novadaq Technologies ULC | Métodos para la producción y uso de eritrocitos cargados con sustancias para la observación y el tratamiento de la hemodinámica microvascular |
US20100093648A1 (en) * | 2008-10-09 | 2010-04-15 | Antonio Cruz | Treatment of macular degeneration-related disorders |
KR101018785B1 (ko) * | 2008-11-28 | 2011-03-03 | 삼성전기주식회사 | 전자기 밴드갭 구조물 및 회로 기판 |
MX2011011044A (es) | 2009-04-22 | 2011-11-04 | Merck Patent Gmbh | Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados. |
US10492671B2 (en) | 2009-05-08 | 2019-12-03 | Novadaq Technologies ULC | Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest |
US20140004510A1 (en) | 2010-09-24 | 2014-01-02 | Massachusetts Eye And Ear Infirmary | Methods and compositions for prognosing and/or detecting age-related macular degeneration |
JP6215203B2 (ja) * | 2011-08-23 | 2017-10-18 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co. Ltd | 眼疾患および障害の治療用の(バクテリオ)クロロフィル光増感剤 |
US9211214B2 (en) | 2012-03-21 | 2015-12-15 | Valeant Pharmaceuticals International, Inc | Photodynamic therapy laser |
EP2863801B8 (en) | 2012-06-21 | 2024-06-12 | Stryker Corporation | Quantification and analysis of angiography and perfusion |
US9962251B2 (en) | 2013-10-17 | 2018-05-08 | Boston Scientific Scimed, Inc. | Devices and methods for delivering implants |
KR102068776B1 (ko) | 2014-09-29 | 2020-01-21 | 노바다크 테크놀러지즈 유엘씨 | 자가형광이 존재하는 생물학적 물질에서 타겟 형광체의 이미징 |
US10631746B2 (en) | 2014-10-09 | 2020-04-28 | Novadaq Technologies ULC | Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography |
CN106620893B (zh) | 2015-07-23 | 2021-07-30 | 爱博诺德(北京)医疗科技股份有限公司 | 用于眼部疾病光治疗的材料 |
JP7079937B2 (ja) | 2016-05-26 | 2022-06-03 | ユニバーシティ オブ ピッツバーグ -オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 肺血管疾患を治療するための組成物および方法 |
EP4242743A3 (en) | 2017-02-10 | 2023-10-18 | Stryker European Operations Limited | Open-field handheld fluorescence imaging systems and methods |
KR20190056758A (ko) | 2017-11-17 | 2019-05-27 | 주식회사 지뉴브 | 종양줄기세포 특성의 암을 치료하기 위한 항암 병용 요법 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179120A (en) | 1991-06-28 | 1993-01-12 | Cytopharm, Inc. | Porphycene compounds for photodynamic therapy |
US5776966A (en) | 1992-05-27 | 1998-07-07 | University Of British Columbia | Selective cell inactivation in blood |
CA2185644C (en) * | 1994-03-14 | 2011-04-12 | Joan W. Miller | Use of green porphyrins in ocular diagnosis and therapy |
JP2961074B2 (ja) * | 1995-09-06 | 1999-10-12 | 明治製菓株式会社 | 光化学療法用の新生血管閉塞剤 |
-
1996
- 1996-03-11 US US08/613,420 patent/US5756541A/en not_active Expired - Lifetime
-
1997
- 1997-02-25 HU HU9902012A patent/HU227978B1/hu unknown
- 1997-02-25 DK DK97903181T patent/DK0894009T3/da active
- 1997-02-25 IL IL126099A patent/IL126099A/en not_active IP Right Cessation
- 1997-02-25 KR KR10-1998-0707147A patent/KR100433507B1/ko not_active IP Right Cessation
- 1997-02-25 WO PCT/CA1997/000134 patent/WO1997033619A1/en active Application Filing
- 1997-02-25 EP EP97903181A patent/EP0894009B1/en not_active Expired - Lifetime
- 1997-02-25 CA CA002248087A patent/CA2248087C/en not_active Expired - Lifetime
- 1997-02-25 DE DE69733943T patent/DE69733943T2/de not_active Expired - Lifetime
- 1997-02-25 PL PL97328796A patent/PL188888B1/pl unknown
- 1997-02-25 CZ CZ0278998A patent/CZ299301B6/cs not_active IP Right Cessation
- 1997-02-25 CN CN97192957A patent/CN1104908C/zh not_active Expired - Lifetime
- 1997-02-25 ES ES97903181T patent/ES2246505T3/es not_active Expired - Lifetime
- 1997-02-25 NZ NZ331736A patent/NZ331736A/en not_active IP Right Cessation
- 1997-02-25 JP JP9532132A patent/JP2000506173A/ja active Pending
- 1997-02-25 AT AT97903181T patent/ATE301473T1/de active
- 1997-03-03 ZA ZA9701820A patent/ZA971820B/xx unknown
- 1997-03-10 AR ARP970100946A patent/AR004422A1/es not_active Application Discontinuation
- 1997-04-30 TW TW086105744A patent/TW448045B/zh not_active IP Right Cessation
-
1998
- 1998-05-22 US US09/083,480 patent/US5910510A/en not_active Expired - Lifetime
- 1998-09-10 NO NO984163A patent/NO984163L/no not_active Application Discontinuation
- 1998-09-11 FI FI981954A patent/FI981954A/fi unknown
-
1999
- 1999-04-28 US US09/300,979 patent/US6548542B1/en not_active Expired - Lifetime
- 1999-07-22 HK HK99103160A patent/HK1018203A1/xx unknown
-
2003
- 2003-03-07 US US10/383,820 patent/US20030149012A1/en not_active Abandoned
-
2004
- 2004-01-26 AR ARP040100227A patent/AR042931A2/es not_active Application Discontinuation
-
2006
- 2006-03-09 JP JP2006064119A patent/JP2006273853A/ja active Pending
-
2007
- 2007-09-10 US US11/852,965 patent/US8239978B2/en not_active Expired - Fee Related
- 2007-11-29 IL IL187758A patent/IL187758A0/en not_active IP Right Cessation
-
2012
- 2012-06-04 IL IL220143A patent/IL220143A0/en unknown
- 2012-06-06 IL IL220210A patent/IL220210A0/en unknown
- 2012-08-13 US US13/584,617 patent/US20120310144A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005018634A1 (fr) * | 2003-08-25 | 2005-03-03 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Ether de monomethyle d'hematoporphyrine utilise pour le traitement de troubles oculaires |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1104908C (zh) | 通过对眼的光动力学治疗改善视力 | |
US6610679B2 (en) | Use of green porphyrins to treat neovasculature in the eye | |
US5707986A (en) | Angiographic method using green porphyrins in primate eyes | |
US8106038B2 (en) | Method for reducing or preventing PDT related inflammation | |
Michels et al. | Photodynamic therapy with verteporfin: a new treatment in ophthalmology | |
DE60225783T2 (de) | Photodynamische therapie mit verminderter bestrahlungsstärke | |
US7060695B2 (en) | Method to prevent vision loss | |
CA2536069C (en) | Use of green porphyrins in ocular diagnosis and therapy | |
AU705100C (en) | Improved vision through photodynamic therapy of the eye | |
JP2012092145A (ja) | 眼の光力学的治療による視力改善用組成物 | |
Levy et al. | Use Of Green Porphyrinsto Treat Neovasculature In The Eyes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: NOVARTIS CO., LTD. Free format text: FORMER OWNER: NONE Effective date: 20031230 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20031230 Address after: British Columbia Co-patentee after: Novartis Vaccines & Diagnostic Patentee after: QLT Phototherapeutics Co., Ltd. Address before: British Columbia Patentee before: QLT Phototherapeutics Co., Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: QLT CO., LTD. Free format text: FORMER NAME OR ADDRESS: QLT PHOTOTHERAPEUTICS INC. |
|
CP03 | Change of name, title or address |
Address after: Novartis Ltd, British Columbia, Canada Co-patentee after: Novartis Vaccines & Diagnostic Patentee after: QLT Plug Delivery Inc Address before: Novartis Ltd, British Columbia, Canada Co-patentee before: Novartis Vaccines & Diagnostic Patentee before: QLT Phototherapeutics Co., Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20030409 |
|
CX01 | Expiry of patent term |